Advertisement

Uterine Cancer pp 329-335 | Cite as

Therapeutic Strategies in Recurrent and Metastatic Endometrial Cancer

  • Lalit Kumar

Abstract

Adjuvant postoperative treatment recommendations in advanced stage disease are widely disparate and an area of active research. Assuming an adequate performance status, virtually all women with advanced stage disease (stage III and IV) will need chemotherapy,external beam pelvic radiotherapy with or without an extended para-aortic field. Improved understanding of molecular biology of endometrial cancer and identification of potential pathways has led to the development of targeted therapies. Currently, a number of these are under active investigations and current status will be dealt with.

Keywords

Endometrial Cancer Serous Carcinoma Gynecology Oncology Group Endometrial Cancer Patient Serous Ovarian Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.CrossRefPubMedGoogle Scholar
  2. 2.
    ICMR Cancer Registry: ICMR National Cancer Registry Programme. http://www.icmr.nic.in/ncrp/cancer_reg.htm
  3. 3.
    Tsikouras P, Bouchlariotou S, Vrachnis N, et al. Endometrial cancer: molecular and therapeutic aspects. Eur J Obstet Gynecol Reprod Biol. 2013;169:1–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Plataniotis G, Castiglione M, et al. On behalf of the ESMO Guidelines Working Group Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v41–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Rauh-Hain JA, del Carmen Marcela G. Treatment for advanced and recurrent endometrial carcinoma: combined modality. Oncologist. 2010;15:852–61.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Nogami Y, Banno K, Kisu I, et al. Current status of molecular-targeted drugs for endometrial cancer (review). Mol Clin Oncol. 2013;1(5):799–804.PubMedCentralPubMedGoogle Scholar
  7. 7.
    Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S105–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Powell MA. Debate: paclitaxel plus carboplatin as systemic therapy for endometrial cancer: PRO: systemic therapy for all endometrial cancers should be paclitaxel plus carboplatin. Clin Ovarian Cancer. 2010;3(1):14–7.CrossRefGoogle Scholar
  9. 9.
    Matoda M, Omatsu K, Yamamoto A, et al. Importance of platinum free interval in second line chemotherapy for advanced recurrent endometrial cancer. Eur J Gynaecol Oncol. 2014;35:224–9.PubMedGoogle Scholar
  10. 10.
    Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecological Oncology Group study. J Clin Oncol. 2004;22:159–66.CrossRefGoogle Scholar
  11. 11.
    Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev. 2012;8:CD003915.PubMedGoogle Scholar
  12. 12.
    Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259–65.PubMedCentralCrossRefPubMedGoogle Scholar
  13. 13.
    Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(3):538–43.PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Castonguay V, Lheureux S, Welch S, et al. A phase II trial of sunitinib in women with metastatic or recurrent endometrial carcinoma: a study of the Princess Margaret, Chicago and California Consortia. Gynecol Oncol. 2014;134(2):274–80.CrossRefPubMedGoogle Scholar
  15. 15.
    Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117(1):37–40.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(3):486–94.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319–25.CrossRefPubMedGoogle Scholar
  18. 18.
    Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15–20.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol and tamoxifen for endometrial cancer: a Gynecological Oncology Group study. Gynecol Oncol. 2014;132:585–92.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108(9):1771–7.PubMedCentralCrossRefPubMedGoogle Scholar
  21. 21.
    Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108(5):1021–6.PubMedCentralCrossRefPubMedGoogle Scholar
  22. 22.
    Tsoref D, Welch S, Lau S, Biagi J, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135(2):184–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer India 2015

Authors and Affiliations

  1. 1.Department of Medical OncologyAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations